文献速递胸部肿瘤

单药Divarasib治疗KRAS G12C阳性非小细胞肺癌:I期研究长期随访

Single-Agent Divarasib in Patients With KRAS G12C-Positive Non-Small Cell Lung Cancer: Long-Term Follow-Up of a Phase I Study.
PubMed 文献 · J Clin Oncol · 2025-07-09

该研究为正在进行的开放标签多中心I期研究(NCT04449874),报告单药divarasib治疗晚期KRAS G12C阳性非小细胞肺癌的长期随访结果。65例患者接受每日一次口服divarasib 50-400 mg,31例(48%)治疗超过1年。基线可测量病灶患者(n=63)确认客观缓解率为55.6%(95% CI,42.5至68.1),中位缓解持续时间为18.0个月(95% CI,11.1至24.9)。

要点

  • 65例晚期KRAS G12C阳性NSCLC患者接受单药divarasib 50-400 mg每日一次口服,31例(48%)治疗超过1年。
  • 基线可测量病灶患者(n=63)确认客观缓解率55.6%(95% CI,42.5至68.1),中位缓解持续时间18.0个月(95% CI,11.1至24.9)。
  • 总体人群(N=65)中位无进展生存期13.8个月(95% CI,9.8至25.4),400 mg剂量组(n=44)为15.3个月(95% CI,12.3至26.1)。

核心结论

  • 延长随访后,divarasib在晚期KRAS G12C阳性非小细胞肺癌患者中显示出长期安全性和抗肿瘤活性。

研究设计与样本

  • 正在进行的开放标签多中心I期研究(ClinicalTrials.gov标识符:NCT04449874),主要目的为安全性,其他目的包括初步抗肿瘤活性。
  • 65例晚期KRAS G12C阳性非小细胞肺癌患者接受单药口服divarasib 50-400 mg每日一次,31例(48%)治疗超过1年。

主要发现

  • divarasib继续显示良好耐受性,超过1年的安全性特征与总体安全性特征一致。
  • 基线可测量病灶的各剂量水平患者(n=63)确认客观缓解率为55.6%(95% CI,42.5至68.1),中位缓解持续时间为18.0个月(95% CI,11.1至24.9)。
  • 总体人群(N=65)中位无进展生存期为13.8个月(95% CI,9.8至25.4)。
  • 400 mg剂量组(n=44)中位无进展生存期为15.3个月(95% CI,12.3至26.1)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Divarasib (GDC-6036), an oral, highly potent and selective next-generation KRAS G12C inhibitor, has demonstrated a manageable safety profile and promising antitumor activity in patients with advanced KRAS G12C-positive non-small cell lung cancer (NSCLC). Here, we report long-term (≥1 year) follow-up of single-agent divarasib from the ongoing, open-label, and multicenter phase I study (ClinicalTrials.gov identifier: NCT04449874). The primary objective was safety, and the other objectives included preliminary antitumor activity. Overall, 65 patients with advanced KRAS G12C-positive NSCLC received single-agent oral divarasib 50-400 mg once daily and 31 patients (48%) were treated beyond 1 year. Divarasib continued to be well tolerated, and the safety profile beyond 1 year was consistent with the overall safety profile. In patients with measurable disease at baseline across all dose levels (n = 63), the confirmed objective response rate was 55.6% (95% CI, 42.5 to 68.1), and the median duration of response was 18.0 months (95% CI, 11.1 to 24.9). The median progression-free survival was 13.8 months (95% CI, 9.8 to 25.4) in the overall population (N = 65) and 15.3 months (95% CI, 12.3 to 26.1) among patients assigned to the 400-mg dose level (n = 44). With extended follow-up, divarasib demonstrated long-term safety and antitumor activity in patients with advanced KRAS G12C-positive NSCLC.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Sacher AG, Miller WH, Patel MR, et al. Single-Agent Divarasib in Patients With KRAS G12C-Positive Non-Small Cell Lung Cancer: Long-Term Follow-Up of a Phase I Study. J Clin Oncol. 2025. PMID: 40632992. doi:10.1200/JCO-25-00040

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。